The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Depression‐resistant endophenotype in mice overexpressing cannabinoid CB 2 receptors
Open accessAbstract
Background and purpose: The present study evaluated the role of CB 2 receptors in the regulation of depressive‐like behaviours. Transgenic mice overexpressing the CB 2 receptor (CB2xP) were challenged with different types of acute and chronic experimental paradigms to evaluate their response in terms of depressive‐like behaviours. Experimental approach: Tail suspension test (TST), novelty‐suppressed feeding test (NSFT) and unpredictable chronic mild stress tests (CMS) were carried out in CB2xP mice. Furthermore, acute and chronic antidepressant‐like effects of the CB 2 receptor‐antagonist AM630 were evaluated by means of the forced swimming test (FST) and CMS, respectively, in wild‐type (WT) and CB2xP mice. CB 2 gene expression, brain‐derived neurotrophic factor (BDNF) gene and protein expressions were studied in mice exposed to CMS by real‐time PCR and immunohistochemistry, respectively. Key results: Overexpression of CB 2 receptors resulted in decreased depressive‐like behaviours in the TST and NSFT. CMS failed to alter the TST and sucrose consumption in CB2xP mice. In addition, no changes in BDNF gene and protein expression were observed in stressed CB2xP mice. Interestingly, acute administration of AM630 (1 and 3 mg·kg −1 , i.p.) exerted antidepressant‐like effects on the FST in WT, but not in CB2xP mice. Chronic administration of AM630 for 4 weeks (1 mg·kg −1 ; twice daily, i.p.) blocked the effects of CMS on TST, sucrose intake, CB 2 receptor gene, BDNF gene and protein expression in WT mice. Conclusion and implications: Taken together, these results suggest that increased CB 2 receptor expression significantly reduced depressive‐related behaviours and that the CB 2 receptor could be a new potential therapeutic target for depressive‐related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mice over-expressing CB2 have reduced vulnerability to CUS and depression-like behaviors at baseline [41, 42]”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [41]
In the citing paper
“ectopic genetic overexpression CB2R in mice (Racz et al., 2008) may mitigate behavioral reactions to chronic stress (Garcia-Gutierrez et al., 2010).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Garcia-Gutierrez et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D. J., Fur, G. L., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,776
Cited by
Sorted by citations
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
The chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959
Agudelo, L. Z., Femenía, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, J. C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.051 · Cited by 739
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 435
Plant derived substances with anti-cancer activity: from folklore to practice
Fridlender, M., Kapulnik, Y., & Koltai, H. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00799 · Cited by 434
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · FEBS Journal · doi:10.1111/febs.12260 · Cited by 418
Zhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334
Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., & Ojha, S. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.003 · Cited by 291
Reinforcement learning in depression: a review of computational research
Chen, C., Takahashi, T., Nakagawa, S., Inoue, T., & Kusumi, I. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.005 · Cited by 233
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
The molecular and cellular mechanisms of depression: a focus on reward circuitry
Fox, M. E., & Lobo, M. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0415-3 · Cited by 232
Brain cannabinoid receptor 2: expression, function and modulation
Chen, D., Gao, M., Gao, F., Quan-xi, S., & Wu, J. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.149 · Cited by 216
Progress in brain cannabinoid CB2 receptor research: From genes to behavior
Jordan, C. J., & Xi, Z. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.026 · Cited by 207
Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice
Ortega-Álvaro, A., Aracil-Fernández, A., García‐Gutiérrez, M. S., Navarrete, F., & Manzanares, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.34 · Cited by 190
Self-citationden Boon, F. S., Chameau, P. J. P., Schaafsma-Zhao, Q., van Aken, W., Bari, M., Oddi, S., Kruse, C. G., Maccarrone, M., Wadman, W. J., & Werkman, T. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118167109 · Cited by 190
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity
Onaivi, E. S., Ishiguro, H., Gu, S., & Liu, Q. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111400652 · Cited by 190
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 188
Endocannabinoid system, stress and HPA axis
Micale, V., & Drago, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.039 · Cited by 189
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 179
Expression of functional cannabinoid CB 2 receptor in VTA dopamine neurons in rats
Zhang, H., Gao, M., Shen, H., Bi, G., Yang, H., Liu, Q., Wu, J., Gardner, E. L., Bonci, A., & Xi, Z. (2016) · Addiction Biology · doi:10.1111/adb.12367 · Cited by 156
García-Gutiérrez, M. S., & Manzanares, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379507 · Cited by 153
Self-citationCannabidiol reduces ethanol consumption, motivation and relapse in mice
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 158
Self-citationNavarro, G., Morales, P., Rodríguez‐Cueto, C., Fernández‐Ruíz, J., Jagerovic, N., & Franco, R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00406 · Cited by 150
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139
García‐Gutiérrez, M. S., García‐Bueno, B., Zoppi, S., Leza, J. C., & Manzanares, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01625.x · Cited by 137
Self-citationEndocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 146
Self-citationMcLaughlin, R. J., Hill, M. N., & Gorzalka, B. B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.006 · Cited by 142
García‐Gutiérrez, M. S., Ortega-Álvaro, A., Busquets-García, A., Pérez‐Ortiz, J. M., Caltana, L. R., Ricatti, M. J., Brusco, A., Maldonado, R. J., & Manzanares, J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.034 · Cited by 126
Self-citationViveros, M., Llorente, R., Suárez, J., Llorente‐Berzal, A., López‐Gallardo, M., & de Fonseca, F. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408956 · Cited by 128
Aracil-Fernández, A., Trigo, J. M., García‐Gutiérrez, M. S., Ortega-Álvaro, A., Ternianov, A., Navarro, D., Robledo, P., Berbel, P. J., Maldonado, R. J., & Manzanares, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.22 · Cited by 119
Self-citationGorzalka, B. B., & Hill, M. N. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.021 · Cited by 120
Role of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 118
Self-citationNeurochemical basis of cannabis addiction
Maldonado, R. J., Berrendero, F., Ozaita, A., & Robledo, P. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.035 · Cited by 113
Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids
Puighermanal, E., Busquets-García, A., Maldonado, R. J., & Ozaita, A. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0384 · Cited by 104
Regulatory role of the cannabinoid CB2receptor in stress‐induced neuroinflammation in mice
Zoppi, S., Madrigal, J. L. M., Caso, J. R., García‐Gutiérrez, M. S., Manzanares, J., Leza, J. C., & García‐Bueno, B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12607 · Cited by 99
Self-citationThe cannabinoid system and microglia in health and disease
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem‐Taylor, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108555 · Cited by 103
Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain
Porta, C. L., Bura, S. A., Llorente‐Onaindia, J., Pastor, A., Navarrete, F., García‐Gutiérrez, M. S., de la Torre, R., Manzanares, J., Monfort, J., & Maldonado, R. J. (2015) · Pain · doi:10.1097/j.pain.0000000000000260 · Cited by 97
Self-citationIgnatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., & Damaj, M. I. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3117-6 · Cited by 88
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Roche, M., & Finn, D. P. (2010) · Pharmaceuticals · doi:10.3390/ph3082517 · Cited by 88
Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus
Li, Y., & Kim, J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.08.053 · Cited by 78
Ma, Z., Gao, F., Larsen, B., Gao, M., Luo, Z., Chen, D., Ma, X., Qiu, S., Zhou, Y., Xie, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.040 · Cited by 74
Rahimian, R., Belliveau, C., Chen, R., & Mechawar, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871997 · Cited by 77
Cannabinoid CB2 receptor‐mediated regulation of impulsive‐like behaviour in DBA/2 mice
Navarrete, F., Pérez‐Ortiz, J. M., & Manzanares, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01542.x · Cited by 72
Self-citationCB1 cannabinoid receptor-mediated aggressive behavior
Rodríguez‐Arias, M., Navarrete, F., Daza‐Losada, M., Navarro, D., Aguilar, M. A., Berbel, P. J., Miñarro, J., & Manzanares, J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.013 · Cited by 72
Self-citationNeuronal populations mediating the effects of endocannabinoids on stress and emotionality
Häring, M., Guggenhuber, S., & Lutz, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.035 · Cited by 72
CB2 receptor in the CNS: From immune and neuronal modulation to behavior
Grabon, W., Rheims, S., Smith, J., Bodennec, J., Belmeguenaï, A., & Bezin, L. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105226 · Cited by 67
Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?
Boorman, E., Zajkowska, Z., Ahmed, R., Pariante, C. M., & Zunszain, P. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4105-9 · Cited by 68
Gamaleddin, I., Zvonok, A. M., Makriyannis, A., Goldberg, S. R., & Foll, B. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029900 · Cited by 66
Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression
Hwang, E., Kim, H.-B., Lee, S., Kim, M. J., Kim, K.-J., Han, G., Han, S.-Y., Lee, E.-A., Yoon, J.-H., Kim, D., et al. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112439 · Cited by 69
García‐Gutiérrez, M. S., Navarrete, F., Navarro, G., Reyes‐Resina, I., Franco, R., Lanciego, J. L., Giner, S., & Manzanares, J. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0610-y · Cited by 67
Self-citationEffects of cannabidiol plus naltrexone on motivation and ethanol consumption
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Fraguas‐Sánchez, A. I., Torres‐Suárez, A. I., & Manzanares, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14380 · Cited by 68
Self-citationCannabinoid Modulation of the Stressed Hippocampus
Scarante, F. F., Vila-Verde, C., Lopes, V. D., Ferreira‐Junior, N. C., Guimarães, F. S., & Campos, A. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00411 · Cited by 66
New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Kibret, B. G., Ishiguro, H., Horiuchi, Y., & Onaivi, E. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020975 · Cited by 69
Bambico, F. R., Hattan, P. R., Garant, J.-P., & Gobbi, G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.006 · Cited by 61
Vlachou, S., & Panagis, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990433 · Cited by 62
Ternianov, A., Pérez‐Ortiz, J. M., Solesio, M. E., García‐Gutiérrez, M. S., Ortega-Álvaro, A., Navarrete, F., Leiva, C., Galindo, M. F., & Manzanares, J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.012 · Cited by 59
Self-citationZhang, H., Shen, H., Jordan, C. J., Liu, Q., Gardner, E. L., Bonci, A., & Xi, Z. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0037-3 · Cited by 57
Evens, N., Vandeputte, C., Muccioli, G. G., Lambert, D. M., Baekelandt, V., Verbruggen, A., Debyser, Z., Laere, K. V., & Bormans, G. M. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.033 · Cited by 56
Preclinical Evidence of Rapid-Onset Antidepressant-Like Effect in Radix Polygalae Extract
Shin, I.-J., Son, S. U., Park, H., Kim, Y., Park, S. H., Swanberg, K. M., Shin, J.-Y., Ha, S.-K., Cho, Y., Bang, S. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088617 · Cited by 57
Franklin, J. M., & Carrasco, G. A. (2012) · Synapse · doi:10.1002/syn.21626 · Cited by 56
Cannabinoids in depressive disorders
Poleszak, E., Wośko, S., Sławińska, K., Szopa, A., Wróbel, A., & Serefko, A. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.058 · Cited by 56
Álvaro-Bartolomé, M., & Garcı́a-Sevilla, J. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.035 · Cited by 54
Romero‐Zerbo, S., García‐Gutiérrez, M. S., Suárez, J., Rivera, P., Ruz‐Maldonado, I., Vida, M., de Fonseca, F. R., Manzanares, J., & Bermúdez‐Silva, F. J. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02325.x · Cited by 51
Self-citationLifschytz, T., Broner, E. C., Zozulinsky, P., Slonimsky, A., Eitan, R., Greenbaum, L., & Lerer, B. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001453 · Cited by 51
CB2 cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons
Atwood, B. K., Straiker, A. J., & Mackie, K. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.024 · Cited by 50
Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice
Austrich-Olivares, A., García‐Gutiérrez, M. S., Illescas, L., Gasparyan, A., & Manzanares, J. (2022) · Pharmaceuticals · doi:10.3390/ph15040473 · Cited by 52
Self-citationRole of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence
Micale, V., Tabiová, K., Kučerová, J., & Drago, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_5 · Cited by 47
Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
Rodrigues, R. S., Lourenço, D. M., Paulo, S. L., Mateus, J. M., Ferreira, M. F., Mouro, F. M., Moreira, J. B., Ribeiro, F. F., Sebastião, A. M., & Xapelli, S. (2019) · Molecules · doi:10.3390/molecules24071350 · Cited by 47
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Morris, G., Walder, K. R., Kloiber, S. M., Amminger, G. P., Berk, M., Bortolasci, C. C., Maes, M. H. J., Puri, B. K., & Carvalho, A. F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105729 · Cited by 48
Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
Morcuende, Á., García‐Gutiérrez, M. S., Tambaro, S., Nieto, E. O., Manzanares, J., & Femenía, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.866052 · Cited by 45
Self-citationRicardi, C., Barachini, S., Consoli, G., Marazziti, D., Polini, B., & Chiellini, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063203 · Cited by 51
Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system
Khakpai, F., Ebrahimi-Ghiri, M., Alijanpour, S., & Zarrindast, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108717 · Cited by 44
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
Navarro, D., Gasparyan, A., Navarrete, F., Torregrosa, A. B., Rubio, G., Marín, M., Acosta, G. B., García‐Gutiérrez, M. S., & Manzanares, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094764 · Cited by 47
Self-citationModulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence
Bright, U., & Akirav, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105526 · Cited by 48
Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 45
Franklin, J. M., & Carrasco, G. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112450786 · Cited by 42
Role of CB2 receptors in social and aggressive behavior in male mice
Rodríguez‐Arias, M., Navarrete, F., Blanco-Gandía, M. C., Arenas, M. C., Aguilar, M. A., Bartoll-Andrés, A., Valverde, O., Miñarro, J., & Manzanares, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3939-5 · Cited by 41
Self-citationTchekalarova, J. D., Machado, K. D. C., Júnior, A. L. G., Cavalcante, A. A. D. C. M., Momchilova, A., & Tzoneva, R. (2018) · Seizure · doi:10.1016/j.seizure.2018.03.009 · Cited by 40
The Endocannabinoid/Endovanilloid System and Depression
Smaga, I., Bystrowska, B., Gawliński, D., Przegaliński, E., & Filip, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140923205412 · Cited by 40
CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice
Khella, R., Short, J. L., & Malone, D. T. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3481-x · Cited by 38
Henry, R. J., Kerr, D. M., Finn, D. P., & Roche, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.006 · Cited by 39
de Oliveira, R. M. W., de Oliveira, C. L., Guimarães, F. S., & Campos, A. C. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.11 · Cited by 38
Anxious behavior induces elevated hippocampal Cb2 receptor gene expression
Robertson, J. M., Achua, J. K., Smith, J. P., Prince, M. A., Staton, C. D., Ronan, P. J., Summers, T. R., & Summers, C. H. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.061 · Cited by 36
Navarrete, F., García‐Gutiérrez, M. S., & Manzanares, J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.041 · Cited by 36
Self-citationMorris, G., Sominsky, L., Walder, K. R., Berk, M., Marx, W., Carvalho, A. F., Bortolasci, C. C., Maes, M. H. J., & Puri, B. K. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02800-y · Cited by 38
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential
Gasperi, V., Guzzo, T., Topai, A., Gambacorta, N., Ciriaco, F., Nicolotti, O., & Maccarrone, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220825161603 · Cited by 34
García‐Cabrerizo, R., & García-Fuster, M. J. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.018 · Cited by 35
Hosoya, T., Fukumoto, D., Kakiuchi, T., Nishiyama, S., Yamamoto, S., Ohba, H., Tsukada, H., Ueki, T., Sato, K., & Ouchi, Y. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0851-4 · Cited by 34
Lazáry, J., Eszlári, N., Juhász, G., & Bagdy, G. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.083 · Cited by 34
Giacobbe, J., Marrocu, A., Benedetto, M. G. D., Pariante, C. M., & Borsini, A. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.12.024 · Cited by 36
Role of hypothalamic cannabinoid receptors in post-stroke depression in rats
Wang, S., Sun, H., Liu, S., Wang, T., Guan, J.-Q., & Jia, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.01.006 · Cited by 33
Gómez‐Cañas, M., Morales, P., García‐Toscano, L., Navarrete, C. M., Muñóz, E., Jagerovic, N., Fernández‐Ruíz, J., Garcı́a-Arencibia, M., & Pazos, M. R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.021 · Cited by 32
Russo, E., Chimirri, S., Aiello, R., Fazio, S. D., Leo, A., Rispoli, V., Marra, R., Labate, A., Fazio, P. D., Citraro, R., et al. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.05.002 · Cited by 32
Bystrowska, B., Frankowska, M., Smaga, I., Pomierny-Chamioło, L., & Filip, M. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9910-6 · Cited by 31
Targeting 2‐arachidonoylglycerol signalling in the neurobiology and treatment of depression
Silveira, K. M., Wegener, G., & Joca, S. R. L. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13595 · Cited by 30
Carey, L. M., Xu, Z., Rajic, G., Makriyannis, A., Romero, J., Hillard, C. J., Mackie, K., & Hohmann, A. G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106560 · Cited by 30
Changes in the cannabinoids receptors in rats following treatment with antidepressants
Smaga, I., Zaniewska, M., Gawliński, D., Faron‐Górecka, A., Szafrański, P. W., Cegla, M. T., & Filip, M. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.08.012 · Cited by 30
Towards a Personalized Treatment in Depression: Endocannabinoids, Inflammation and Stress Response
Zajkowska, Z., Englund, A., & Zunszain, P. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.40 · Cited by 30
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
Ishiguro, H., Kibret, B. G., Horiuchi, Y., & Onaivi, E. S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.828895 · Cited by 29
Are CB2 Receptors a New Target for Schizophrenia Treatment?
Cortez, I. L., da Silva, N. R., Guimarães, F. S., & Gomes, F. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.587154 · Cited by 29
Metadata
- Authors
- García‐Gutiérrez, M., Pérez‐Ortiz, J., Gutiérrez‐Adán, A., & Manzanares, J.
- Affiliations
- Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (ES)
- Instituto de Neurociencias (ES)
- Corresponding author
- Manzanares, J
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-04-26
- Volume
- 160
- Issue
- 7
- Pages
- 1773-1784
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2936848
- OpenAlex
- W2054653962
- Cited by
- 196
- References
- 69
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 6 · 2023: 13 · 2022: 20 · 2021: 19 · 2020: 9 · 2019: 12 · 2018: 14 · 2017: 11 · 2016: 8 · 2015: 10 · 2014: 13 · 2013: 11 · 2012: 15
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- British Journal of Pharmacology (publishedVersion, public-domain)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Ministerio de Ciencia e Innovación (RETICS RD06/0001/1004, SAF 2008-01106)
- Plan Nacional sobre Drogas
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- CB2 receptor, depression, depression-like behavior, AM630, antidepressant-like effects, chronic unpredictable mild stress, brain-derived neurotrophic factor, endophenotypes, tail suspension test, forced swim test, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Anxiety, Behavior, Animal, Depression, Disease Models, Animal, Feeding Behavior, Hippocampus, Immunohistochemistry, Indoles, Male, Mice, Inbred ICR, Mice, Transgenic, Restraint, Physical, Stress, Psychological, Swimming, Gene Expression, Brain-Derived Neurotrophic Factor, Receptor, Cannabinoid, CB2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
